All In Biotech

Drug Trial Radar · NCT00979745

Phase III Confirmatory Study in Erythropoietic Protoporphyria (EPP)

A Phase III, Multicentre, Double-Blind, Randomised, Placebo-Controlled Study to Confirm the Safety and Efficacy of Subcutaneous Bioresorbable Afamelanotide Implants in Patients With Erythropoietic Protoporphyria (EPP)

Last checked: Nov 20, 2026Latest source record: Oct 12, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

74

Actual

Start

Sep 2009

Primary completion

May 2011

Study completion May 2011

Sponsor

Sponsor type
Industry
First posted
Sep 18, 2009

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Afamelanotide is a man-made drug being studied for use as a preventative medication for EPP sufferers. It is a synthetically produced analogue of human alpha melanocyte stimulating hormone (alpha-MSH) and is not yet available on the market. The purpose of this study is to look at whether afamelanotide can reduce the number and severity of EPP symptoms when patients are exposed to light. This study will also look at how the drug is tolerated when taken by people with EPP. The study will involve the use of an implant, which comes in the form of a small rod (approximately 2 cm x 0.15 cm) to be administered under the skin. The implant may contain the study drug afamelanotide or a placebo (inactive medication). Over 450 subjects have been treated with afamelanotide to date with no serious safety concerns identified. For this study, afamelanotide has been formulated as a controlled release depot injection (implant). This means that the afamelanotide will be released slowly into the body over a few days. Once inserted, the implant will remain in the body after afamelanotide has been released and will slowly dissolve. This study will help to provide more information about afamelanotide. This information will be used to determine the safety and efficacy (the ability of the drug to produce an effect) of this drug in EPP sufferers. Up to 70 people will participate in this study from study sites across Europe.

Conditions

  • Erythropoietic Protoporphyria

Interventions

  • AfamelanotideDrug

    One 16mg subcutaneous implant every 2 months for 9 months.

  • PlaceboDrug

    One 16mg subcutaneous implant every 2 months for 9 months.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The Duration of Direct Sunlight Exposure Between 10:00 and 15:00 Hours on Days When Patients Did Not Report Phototoxicity-related Pain (Likert Pain Scale Score of 0)Time frame: From baseline to Day 270

Locations

8 sites in 6 countries. Site status is shown where the registry gives one.

  • HUS:n Iho-ja allergiasairaala (Skin and Allergy Hospital)

    Helsinki, Finland

  • Centre Français des Porphyries, Hôpital Louis Mourier

    Colombes, Cedex, France

  • Department of Dermatology , Heinrich-Heine-University Duesseldorf

    Düsseldorf, Germany

  • Beaumont Hospital, Department of Dermatology

    Dublin, Ireland

  • Academisch Ziekenhuis Maastricht

    Maastricht, Netherlands

  • Erasmus Medical Center

    Rotterdam, Netherlands

  • Photobiology Unit - Hope Hospital, University of Manchester

    Manchester, United Kingdom

  • St Woolos Hospital

    Newport, Wales, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.